Jaguar Health, Inc.
As of Oct 22, 2026, Jaguar Health is in Stage 4, the downtrend phase, now in week 118 (since Jun 20, 2024). It closed at $2.15, 99.8% below its 52-week high and below its 200-day average, which is falling.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is JAGX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
JAGX among Biotechnology550th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …550 | JAGX | Stage 4 · wk 118 | 2 | −75.9% |
Jaguar Health: quick answers
What stage is Jaguar Health in?
As of Oct 22, 2026, Jaguar Health (JAGX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 20, 2024 and is in week 118. What the four stages mean
Is Jaguar Health in an uptrend?
No. Jaguar Health is in a Stage 4 downtrend. It trades 98.4% below its 200-day average, which is falling.
How far is Jaguar Health from its 52-week high?
Jaguar Health closed at $2.15 on Oct 22, 2026, 99.8% below its 52-week high of $1,102.50. Its 52-week low is $2.15.
How has Jaguar Health performed over the past year?
As of Oct 22, 2026, Jaguar Health is down 99.8% over the past year and down 99.6% so far in 2026.
Which sector and industry is Jaguar Health in?
Jaguar Health is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.